Business Context and Reporting Period
This Form 8-K Current Report was filed by Abbott Laboratories on September 9, 2019. The report details corporate governance changes effective as of the filing date, specifically regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document focuses exclusively on corporate governance events and does not contain financial performance data.
Material Changes
- Board Appointment: General Darren W. McDew was named to the Abbott Laboratories Board of Directors on September 9, 2019.
- Bylaw Amendment: The Board amended Article III, Section 2 of the By-laws to increase the number of directors from thirteen to fourteen, effective September 9, 2019.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The report is limited to the announcement of the new director and the corresponding bylaw amendment.
Investor Verification Checklist
- Verify the background and qualifications of the newly appointed director, General Darren W. McDew.
- Confirm the updated composition of the Board of Directors (now 14 members) in subsequent proxy statements or governance reports.
- Review the full text of the amended By-laws (Exhibit 3.1) for any other potential governance changes.